Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
- Category: Antibodies
- Published on Monday, 11 September 2017 18:15
- Hits: 1148
Confirmed Objective Response Rate (ORR) of 34%, Two Confirmed Complete Responses (CRs) and Twelve Confirmed Partial Responses (PRs)
Median Duration of Response (DOR) of 12.6 Months
Median Progression-Free Survival (PFS) of 7.1 Months
Interim Phase 2 Results Reported at European Society for Medical Oncology (ESMO) 2017 Congress
MADRID, Spain I September 11, 2017 I Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that sacituzumab govitecan (IMMU-132) is active in patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to chemotherapies and immune checkpoint inhibitors (IOs).
“The results in patients relapsed or refractory to IO therapies are particularly encouraging, since few options are available after they become refractive,” commented Dr. Scott T. Tagawa, the Richard A. Stratton Associate Professor in Hematology and Oncology, and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine and an oncologist at NewYork-Presbyterian, who presented the results at the ESMO conference.
“Despite the fact that five IOs have been approved in the U.S. for patients with advanced bladder cancer following platinum chemotherapy,1 only about 15% to 25% of patients responded to the new treatments. I believe IMMU-132 has the potential to become a second or later line treatment to platinum- or IO-based therapy,” added Dr. Tagawa.
In the single-arm Phase 2 study with IMMU-132, the confirmed ORR among forty-one intention-to-treat patients was 34% (14/41), including two confirmed CRs and twelve confirmed PRs. While eight of the fourteen responders are ongoing and are still receiving treatment, including four long-term responses greater than 1 year and two currently ongoing at 15 and 22 months, the median DOR at the time of data cutoff was 12.6 months (95% confidence interval [CI], 7.5 to 12.9 months). Median PFS at 80% data maturity was 7.1 months (95% CI, 5.0 to 10.7 months).
The enrolled cohort included fourteen patients who progressed after prior IO therapy, eleven of whom received IMMU-132 as the fourth or later line of therapies. Despite the late-stage setting, the confirmed ORR in this subset of patients was 29% (4/14), with median PFS of 5.4 months (95% CI, 1.9 to 7.2 months) but median OS was not met. All four responders in this subgroup had three or more prior therapies before IMMU-132.
“In light of these favorable interim results with IMMU-132 in metastatic urothelial cancer, we will approach the regulatory authorities to discuss the appropriate path forward in this disease with continued unmet medical need,” remarked Dr. Behzad Aghazadeh, Chairman of the Board of Immunomedics.
A total of 41 patients with mUC were enrolled into this open-label multicenter study to receive 10 mg/kg of IMMU-132 on days 1 and 8 of 3-week cycles. Median number of doses received was 3 (range, 1-6). Despite repeated dosing, grade 3 or higher adverse events were limited to neutropenia (39%), anemia (10%), diarrhea (7%), and fatigue (7%).
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ most advanced product candidate is IMMU-132 (sacituzumab govitecan), an antibody-drug conjugate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics’ primary goal is to bring IMMU-132 to market for the benefit of patients and the creation of stockholder value. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.